Thyroid Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

Thyroid Cancer Pipeline Drugs Market Report Overview

Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include a lump that can be felt through the skin on the neck, difficulty swallowing, pain in the neck and throat, and swollen lymph nodes in the neck. Predisposing factors include females, high levels of radiation, and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy.

The Thyroid Cancer pipeline market report provides a comprehensive overview of the therapeutics under development for Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects.

Key Targets Proto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 2, Serine/Threonine Protein Kinase B Raf, Programmed Cell Death Protein 1, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Vascular Endothelial Growth Factor Receptor 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, and Dual Specificity Mitogen Activated Protein Kinase Kinase 2
Key Mechanisms of action Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Serine/Threonine Protein Kinase B Raf Inhibitor, Programmed Cell Death Protein 1 Antagonist, Epidermal Growth Factor Receptor Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, and Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor
Key Routes of Administration Oral, Intravenous, Subcutaneous, Intratumor, Intravenous Drip, Parenteral, Intralesional, Intramuscular, Intraperitoneal, Intrathecal, and Intravesical
Key Molecule Types Small Molecule, Monoclonal Antibody, Cell Therapy, Synthetic Peptide, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Recombinant Protein, Fusion Protein, Gene Therapy, and Oncolytic Virus
Major Companies Novartis AG, Advenchen Laboratories LLC, Loxo Oncology Inc, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, CSPC Pharmaceutical Group Ltd, Jiangsu Hengrui Medicine Co Ltd, Merck & Co Inc, and AffyImmune Therapeutics Inc

For more insights on Thyroid Cancer pipeline market, download a free report sample

Key Targets in the Thyroid Cancer Pipeline Drugs Market

In the Thyroid Cancer pipeline drugs market, the key targets are Proto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 2, Serine/Threonine Protein Kinase B Raf, Programmed Cell Death Protein 1, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Vascular Endothelial Growth Factor Receptor 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, and Dual Specificity Mitogen Activated Protein Kinase Kinase 2.

Thyroid Cancer Pipeline Drugs Market, by Targets

Thyroid Cancer Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Thyroid Cancer Pipeline Drugs Market

Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor has the highest number of pipeline products followed by Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Serine/Threonine Protein Kinase B Raf Inhibitor, Programmed Cell Death Protein 1 Antagonist, Epidermal Growth Factor Receptor Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, and Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor.

Thyroid Cancer Pipeline Drugs Market Analysis, by MoA

Thyroid Cancer Pipeline Drugs Market Analysis, by MoA

To get more insights on key MoA, download a free sample report

Thyroid Cancer Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Thyroid Cancer pipeline drug market are oral, intravenous, subcutaneous, intratumor, intravenous drip, parenteral, intralesional, intramuscular, intraperitoneal, intrathecal, and intravesical. Oral has the maximum number of pipeline products.

Thyroid Cancer Pipeline Drugs Market Analysis, by RoA

Thyroid Cancer Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Thyroid Cancer Pipeline Drugs Market

The key molecule types in the Thyroid Cancer pipeline drugs market are small molecule, monoclonal antibody, cell therapy, synthetic peptide, gene-modified cell therapy, monoclonal antibody conjugated, recombinant protein, fusion protein, gene therapy, and oncolytic Virus. Small molecule has the highest number of pipeline products.

Thyroid Cancer Pipeline Drugs Market, by Molecule Types

Thyroid Cancer Pipeline Drugs Market, by Molecule Types

To get more insights on key molecule types, download a free sample report

Major Companies in the Thyroid Cancer Pipeline Drugs Market

The major companies in the Thyroid Cancer pipeline drugs market are Novartis AG, Advenchen Laboratories LLC, Loxo Oncology Inc, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, CSPC Pharmaceutical Group Ltd, Jiangsu Hengrui Medicine Co Ltd, Merck & Co Inc, and AffyImmune Therapeutics Inc.

Novartis AG: Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Thyroid Cancer Pipeline Drugs Market, by Major Companies

Thyroid Cancer Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thyroid Cancer
  • The pipeline guide reviews pipeline therapeutics for Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thyroid Cancer therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thyroid Cancer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Thyroid Cancer

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thyroid Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

ABM Therapeutics Inc
Advanced Accelerator Applications SA
Advenchen Laboratories LLC
AffyImmune Therapeutics Inc
Akeso Inc
Alphamab Oncology
Applied Pharmaceutical Science Inc
Arch Oncology Inc
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Beijing Konruns Pharmaceutical Co Ltd
Bicara Therapeutics Inc
BioMed Valley Discoveries Inc
Biosion Inc
Biovista Inc
Blueprint Medicines Corp
Boston Pharmaceuticals Inc
BridgeBio Pharma Inc
Bristol-Myers Squibb Co
C4 Therapeutics Inc
Calithera Biosciences Inc
CAS-Lamvac Biotech Co Ltd
Cello Therapeutics Inc
Centrose LLC
Chengdu Jinrui Foundation Biotechnology Co Ltd
Codiak BioSciences Inc
CSPC Pharmaceutical Group Ltd
CytImmune Sciences Inc
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Eisai Co Ltd
Eli Lilly and Co
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Genelux Corp
Gilead Sciences Inc
Gradalis Inc
Heilongjiang ZBD Pharmaceutical Co Ltd
Helsinn Group
Hutchison MediPharma Ltd
ImmunityBio Inc
ImmunoForge Co Ltd
Immunome Inc
IngenoVax LLC
InnoCare Pharma Ltd
Innovative Cellular Therapeutics Co Ltd
Intensity Therapeutics Inc
Iovance Biotherapeutics Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Vcare PharmaTech Co Ltd
Johnson & Johnson
Kemimedi Co Ltd
KinaRx LLC
Lepu Biopharma Co Ltd
Lotus Pharmaceutical Co Ltd
Loxo Oncology Inc
MaxiVAX SA
MedGene Therapeutics Inc
Merck & Co Inc
Molecular Targeting Technologies Inc
Novartis AG
Oncorus Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Pionyr Immunotherapeutics Inc
Plexxikon Inc
Plus Therapeutics Inc
PRISM Pharma Co Ltd
Purple Biotech Ltd
Recordati SpA
Regeneron Pharmaceuticals Inc
Sanofi
Savoy Pharmaceuticals Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shouyao Holding Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Sino Biopharmaceutical Ltd
SOTIO Biotech AS
SpringWorks Therapeutics Inc
Statera Biopharma Inc
Suzhou Neupharma Co Ltd
Suzhou SmartNuclide Biopharmaceutical Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Synactix Pharmaceuticals Inc
Tarveda Therapeutics Inc
Theratechnologies Inc
Tiziana Life Sciences Plc
Tmunity Therapeutics Inc
TransThera Sciences (Nanjing) Inc
Trophogen Inc
Turning Point Therapeutics Inc
TYK Medicines Inc
Tyme Inc
Tyra Biosciences Inc
UBI Pharma Inc
UbiVac LLC
Vaccinex Inc
Vascular Biogenics Ltd
Visionary Pharmaceuticals Inc
Xiangxue Life Sciences
Xynomic Pharmaceuticals Holdings Inc
YaoPharma Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Thyroid Cancer – Overview

Thyroid Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Thyroid Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Thyroid Cancer – Companies Involved in Therapeutics Development

Thyroid Cancer – Drug Profiles

Thyroid Cancer – Dormant Projects

Thyroid Cancer – Discontinued Products

Thyroid Cancer – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Thyroid Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Thyroid Cancer – Dormant Projects, 2022

Thyroid Cancer – Dormant Projects, 2022 (Contd..1)

Thyroid Cancer – Dormant Projects, 2022 (Contd..2)

Thyroid Cancer – Dormant Projects, 2022 (Contd..3)

Thyroid Cancer – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Thyroid Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the Thyroid Cancer pipeline drug market?

    In the Thyroid Cancer pipeline drugs market the key targets are Proto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 2, Serine/Threonine Protein Kinase B Raf, Programmed Cell Death Protein 1, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Vascular Endothelial Growth Factor Receptor 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, and Dual Specificity Mitogen Activated Protein Kinase Kinase 2.

  • What are the key mechanisms of action in the Thyroid Cancer pipeline drugs market?

    In the Thyroid Cancer pipeline drugs market the key mechanisms of action are Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Serine/Threonine Protein Kinase B Raf Inhibitor, Programmed Cell Death Protein 1 Antagonist, Epidermal Growth Factor Receptor Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, and Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor.

  • What are the key routes of administration in the Thyroid Cancer pipeline drugs market?

    The key routes of administration in the Thyroid Cancer pipeline drug market are Oral, Intravenous, Subcutaneous, Intratumor, Intravenous Drip, Parenteral, Intralesional, Intramuscular, Intraperitoneal, Intrathecal, and Intravesical. Oral has the maximum number of pipeline products.

  • What are the key molecule types in the Thyroid Cancer pipeline drugs market?

    The key molecule types in the Thyroid Cancer pipeline drug market are Small Molecule, Monoclonal Antibody, Cell Therapy, Synthetic Peptide, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Recombinant Protein, Fusion Protein, Gene Therapy, and Oncolytic Virus.

  • What are the major companies in the Thyroid Cancer pipeline drugs market?

    In the Thyroid Cancer pipeline drugs market the major companies are Novartis AG, Advenchen Laboratories LLC, Loxo Oncology Inc, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, CSPC Pharmaceutical Group Ltd, Jiangsu Hengrui Medicine Co Ltd, Merck & Co Inc, and AffyImmune Therapeutics Inc.

Thyroid Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Thyroid Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Thyroid Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.